1. Bouvy J, Vogler S. Pricing and reimbursement policies: impacts on innovation. In: Kaplan W, Wirtz V, Mantel Teuwisse A, Laing R, editors. Priority medicines for Europe and the world—2013 update. Geneva: World Health Organization; 2013.
2. Paris V, Belloni A. Value in pharmaceutical pricing. OECD Health Working Papers, No. 63. OECD Publishing. 2013. doi: 10.1787/5k43jc9v6knx-en . Accessed 10 Apr 2016.
3. Gerber A, Stock S, Dintsios CM. Reflections on the changing face of German pharmaceutical policy: how far is Germany from value-based pricing? Pharmacoeconomics. 2011;29(7):549–53.
4. Pharmafile. NHS England’s Sovaldi fund: opening the floodgates? 2014. http://www.pharmafile.com/news/190850/nhs-englands-sovaldi-fund-opening-floodgates . Accessed 10 Apr 2016.
5. National Institute for Health and Care Excellence. NICE publishes final drug recommendations for the treatment of 3 separate medical conditions [press release]. 2015. https://www.nice.org.uk/news/press-and-media/nice-publishes-final-drug-recommendations-for-the-treatment-of-3-separate-medical-conditions . Accessed 10 Apr 2016.